KRAS mutations, including G12D, G12V and G13D, are major oncogenic drivers in colorectal cancer (CRC) and are associated with therapeutic resistance. However, approved KRAS inhibitors remain focused on G12C subtype, leaving these prevalent variants without approved targeted therapies. Here, we developed a lipid nanoparticle (LNP)-based RNA interference (RNAi) strategy to target these three KRAS variants using a single small interfering RNA (siRNA) sequence. The developed siRNA-LNPs reduced KRAS mRNA and protein expression in HCT116 (G13D), SW620 (G12V) and LS180 (G12D) cells, but not in KRAS wild-type HT29 cells, suppressing the cellular proliferation, clonogenic survival and migration. Transcriptomic profiling revealed changes in KRAS associated signalling, including suppression of cell-cycle and DNA repair programmes, providing a rationale for combining siRNA silencing with the fluoropyrimidine chemotherapeutic agent 5-fluorouracil (5-FU). The combination produced synergistic effects across all three KRAS-mutant CRC cell models and enhanced the apoptosis in both monolayer cultures and 3D spheroids. Collectively, these findings provide proof of concept for this combination strategy and support its further investigation as a potential therapeutic approach for KRAS-mutant CRC.
The adaptive response to KRASG12C inhibitors (KRASi) in KRASG12C-mutant lung adenocarcinoma models is profile using an integrated genetic, transcriptomic, and mass-spectrometry-based quantitative temporal proteomic platform.
A. Padhye, Kalisa Kang, Fan-Yi Kong et al.· bioRxiv· 0 citations
KRASG12D is a predominant driver in pancreatic cancer, yet the basis of intrinsic resistance to KRASG12D-targeted therapy remains poorly defined. Integrated genomics, transcriptomics, and proteomics profiling across 242 patient-derived organoids (PDOs) and matched tumor tissues reveals a KRASG12D-mutant subset intrinsi...
Ye-Han Zhang, Shi-Jie Tang, Yi Zhang et al.· Cancer Cell· 1 citation
Approximately 20% of cholangiocarcinomas harbor KRAS mutations, with codon 12 variants accounting for most of the cases. Among these, G12V is associated with a poor prognosis, whereas G12D is the most frequent subtype. RMC-6236, a novel RAS (ON) multi-selective inhibitor targeting multiple KRAS codon 12 mutations, has...
S. Yamazaki, N. Hondo, K. Yasukawa et al.· Experimental Hematology & On...· 0 citations
KRAS biology, therapeutic advances, mechanisms of resistance, and emerging strategies that are reshaping the treatment landscape of KRAS-mutant NSCLC are comprehensively summarized.
E. Garbo, P. Scaparone, H. J. Hoe et al.· The Journal of the National...· 0 citations
About 80-90% of sporadic instances of colorectal cancer (CRC) are caused by mutations in the adenomatous polyposis coli (APC) gene, which is one of the earliest and most common molecular events. The constitutive activation of the Wnt/β-catenin signalling pathway caused by APC dysfunction promotes unchecked cellular pro...
Background: Oncogenic alterations in KRAS are among the most frequent driver mutations in human cancers, particularly lung, colorectal, and pancreatic cancers. Mutant KRAS was historically considered an “undruggable” target because of its high affinity for guanosine triphosphate and guanosine diphosphate (GDP) and the...
V. Adhao, Sakshi N. Patil· INNOSC Theranostics and Phar...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.